Zimmer Biomet Q3 sales beat estimates, raises FY outlook
Overview
U.S. medical device maker's Q3 net sales rose 3.1%, slightly beating analyst expectations
Adjusted EPS for Q3 was flat yr/yr and beat analyst expectations
Company raised full-year 2026 organic constant-currency sales growth and adjusted EPS guidance
Outlook
Zimmer Biomet raises 2026 constant currency revenue growth forecast to 4.1%-4.6% from 3.4%-4.4%
Company now expects 2026 organic constant currency revenue growth of 3.0%-3.5%, up from 2.25%-3.25%
Zimmer Biomet raises 2026 adjusted diluted EPS outlook to $8.50-$8.60 from $8.47-$8.59
Result Drivers
PRODUCT MIX - Growth in Hips, S.E.T., and Technology & Data, Bone Cement and Surgical franchises drove overall sales
BROAD-BASED PERFORMANCE - Company cited strong performance across multiple business segments as supporting its updated guidance
COMMERCIAL EXECUTION - Company highlighted U.S. commercial transformation efforts as contributing to performance
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Slight Beat* | $2.06 bln | $2.04 bln (23 Analysts) |
Q3 Adjusted EPS | Beat | $1.90 | $1.88 (24 Analysts) |
Q3 EPS | $1 | ||
Q3 Net Income | $191.60 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy", 20 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Zimmer Biomet Holdings, Inc. is $105.00, about 8.2% above its November 3 closing price of $97.06
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 11 three months ago
Reuters Recommended Reads
Nov 4 - Smith+Nephew cuts outlook after failed orthopaedics deal talks with J&J
Nov 4 - UK's Smith & Nephew misses Q3 revenue estimates, cuts outlook on slower US orthopaedics market
Nov 3 - Strata Critical Medical Q3 revenue beats estimates; announces buyback
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)